Table 3.
Activity | Assay Model | Extracts | Effect/Methodology | Reference |
---|---|---|---|---|
Antioxidant | In vitro |
|
IC50 activity: 1.5 µg/mL for DPPH radicals; 116 µg/mL nitric oxide; 4.7 µg/mL superoxide anion; 27.0 μg/mL hydroxyl radical; potent antioxidant reducing power |
[24] |
In vitro |
|
DPPH radicals scavenging (IC50): 19.17 and 77.8 µg/mL for leaf and stem, respectively |
[68] | |
In vitro |
|
DPPH radicals scavenging (IC50): 459 µg/mL CHCl3 extract; 425 µg/mL EtOAc extracts; 164 µg/mL for n-BuOH |
[26] | |
In vitro |
|
DPPH radicals scavenging (IC50): 792 ± 10 µg/mL |
[46] | |
In vitro |
|
DPPH radicals scavenging (IC50): 59 ± 2 µg/mL for aqueous extracts and 31 ± 2 for ethyl acetate extracts |
[9] | |
In vitro |
|
Greater scavenging of DPPH radicals by ethyl lactate:water (65:35 (v:v)) extracts (approx. 6 mM Trolox/g plant) | [8] | |
Rat liver microsomal preparation |
|
Protection in lipid peroxidation at 104 µg/mL | [24] | |
Rat liver |
|
Protects liver from oxidative stress at 250 and 500 mg/kg for 7 days | [63] | |
Rat |
|
Anti-stress at 125 and 250 mg/kg for 21 days | [64] | |
Human epidermis |
|
Skin protection against oxidative damage. In vitro assays with the reconstituted human epidermis, topical use at 1% | [12] | |
Human hepatocytes |
|
Inhibition of intracellular oxidative stress in HepG2 cells at 250 µg/mL | [26] | |
Cytotoxicity and Antiproliferative activity |
Human cancer cells |
|
Human cervical cancer cell line (HeLa); MTT assay, cell cycle analysis, and topoisomerase II inhibitory activity IC50 value of 4.5 μg/mL; cell arrest at a sub-G phase; promote apoptosis; excellent human topoisomerase II inhibitor at 10 μg/mL |
[67] |
Human cancer cells |
|
No toxicity at 100 µM against human cancer cell lines (SK-MEL, KB, BT-549, and SKOV-3) and two noncancerous kidney cell lines (LLC-PK1 and Vero) | [26] | |
Human cancer cells |
|
Growth inhibition of the three different cell lines of breast (T47D, MCF7) and colon (HCT-116) cancers Ethyl acetate extract exhibited higher activity (IC50 values of 1.57 ± 0.06 mg/mL, 2.2 ± 0.1 mg/mL, and 3.2 ± 0.2 mg/mL for T47D, MCF7, and HCT-116 cells) |
[9] | |
Anti-Inflammatory | Rat |
|
Anti-inflammatory agent at 200 and 400 mg/kg body weight | [68] |
Mousemacrophages |
|
EtOAc and n-ButOH extracts showed inhibition of iNOS with IC50 of 48 and 90 µg/mL, respectively. | [26] | |
Hepatoprotective | Rats |
|
Increase levels of SOD, GS, and GRD parameters in carbon tetrachloride treated wistar albino rats at 250 and 500 mg/kg/day for 7 days | [63] |
Rabbits |
|
Oral administration of extracts at 400 mg/kg/day for 14 days. Reduction in ALP, ALT, AST levels and total bilirubin in carbon tetrachloride treated rabbits | [74] | |
Antimicrobial and Antiprotozoal | Staphylococcus aureus, Bacillus subtilis, Pasture llamultacida |
|
Anti-bacterial activity by disc diffusion method (30 µg/disc): 13.8 ± 0.18 (maximum concentration) | [74] |
Trypanosoma bruces |
|
Antitrypanosomal activity (IC50): 19.48 µg/mL for EtOH extract; 7.99 µg/mL for n-BuOH | [26] | |
Staphylococcus aureus, Bacillus subtilis, Pseud omonas aeruginosa, Escherichia coli |
|
Minimal inhibitory concentration (MIC) assays S. aureus: 0.26 ± 0.09; B. subtilis: 0.42 ± 0.18; P. aeruginosa: 1.67 ± 0.72; E. coli: 1.04 ± 0.36 (values in mg/mL) |
[46] | |
Staphylococcus aureus, Bacillus spp., Escherichia coli, Candida albicans |
|
MIC assayExtract exerted a positive antibacterial action | [8] | |
Staphylococcus aureus |
|
Act as antibiotic adjuvants | [78] | |
Staphylococcus epidermidis, Escherichia coli, P seudomonas aeruginosa, Candida glabrata |
|
Selective and potent antimicrobial activities against the Gram-positive bacterium (S. epidermidis) IC50 of 186 ± 9 μg/mL for aqueous extracts and 92 ± 3 μg/mL for ethyl acetate |
[9] | |
Wound healing | Rats |
|
Excision wound healing model for 14 days; results indicate re-epithelialization and good healing potential using 5% of the extract | [46] |
SK-MEL: Human malignant melanoma; KB: Human epidermoid carcinoma; BT-549: Human ductal carcinoma; SK-OV-3: Human ovary carcinoma; LLC-PK-1: Pig kidney epithelial cells; Vero: African green monkey kidney cell line.